Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers  Ryoichi Onozato, MD,

Published byMelissa O’Neal’ Modified over 5 years ago

Similar presentations

Presentation on theme: "Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers  Ryoichi Onozato, MD,"— Presentation transcript:

1 Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers  Ryoichi Onozato, MD, Takayuki Kosaka, MD, Hiroyuki Kuwano, MD, Yoshitaka Sekido, MD, Yasushi Yatabe, MD, Tetsuya Mitsudomi, MD  Journal of Thoracic Oncology  Volume 4, Issue 1, Pages 5-11 (January 2009) DOI: /JTO.0b013e e0e Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Relative copy number of the MET gene determined by real-time quantitative PCR (polymerase chain reaction) in 24 cell lines and 187 lung cancer specimens. MKN45 and NCI-H1993 cell lines showing MET amplification served as positive controls. Solid triangles indicate samples that had MET splice mutations in the following experiments. Journal of Thoracic Oncology 2009 4, 5-11DOI: ( /JTO.0b013e e0e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Examples of cDNA sequencing chromatograms of the MET gene. In patient T1021, exon 13 was spliced directly to exon 15, skipping exon 14. The chromatogram for the wild type sequence is shown in the upper panel for comparison. Red characters represent a splice mutation. Red arrows indicate the primer position for reverse transcription-polymerase chain reaction (RT-PCR). B, Agarose gel electrophoresis of the RT-PCR product encompassing exon 14 of the MET gene of the paired tumor and normal samples. T, tumor; N, normal lung tissue; N.C, negative control; P.C, positive control. The difference between the larger and smaller bands appears to correspond with length of the exon 14 (141 bp). Journal of Thoracic Oncology 2009 4, 5-11DOI: ( /JTO.0b013e e0e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Sequencing chromatograms of genomic DNA with intronic mutation of the MET gene: Red characters represent deletions or point mutations in genomic DNA. Four intronic mutations were detected in this analysis. B, Diagrammatic representations of the mechanisms for eliminating exon 14 of the MET gene: (i) The 5′ splice site, 3′ splice site, branch site, and polypyrimidine tract are indicated as consensus motifs at the top of figure.24,25,28 Blue arrows indicated primers for polymerase chain reaction (PCR). (ii) Diagrammatic representations of Figure 3A. (iii) Three intronic mutations reported previously by Kong-Beltran et al.9 All intronic mutations detected in this analysis were different from those reported.9 Each mutation is indicated by a red arrow. Py, pyrimidine. Journal of Thoracic Oncology 2009 4, 5-11DOI: ( /JTO.0b013e e0e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Frequencies of MET activation by gene amplification or splice mutation and the mutations of each gene in 211 Japanese patients with lung adenocarcinomas. Thirty percent of the specimens had no mutations of the epidermal growth factor receptor (EGFR), KRAS or HER2 genes and did not show MET activation. Each instance of MET activation detected in this series was mutually exclusionary with these gene mutations. FGFR4 mutation and EML4-ALK fusion gene have been reported to occur in similar exclusionary fashion and be present in 1 of 158 (0.6%) and 5 of 149 (3.4%) of lung adenocarcinomas, respectively, these may be encompassed in the part of Unknown.29,30 Journal of Thoracic Oncology 2009 4, 5-11DOI: ( /JTO.0b013e e0e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers  Ryoichi Onozato, MD,"

Similar presentations

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.
Figure 1. RT–PCR identification of an abnormal transcript of the PTPN6 gene in normal and leukemic bone marrow cells and cell line. (a) Diagrammatic representation.

Figure 1. RT–PCR identification of an abnormal transcript of the PTPN6 gene in normal and leukemic bone marrow cells and cell line. (a) Diagrammatic representation.
Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas  Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas  Rong Fang, PhD, Chao Zheng, PhD, Yihua.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons 

Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons 
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Splicing defects in the CFTR gene: Minigene analysis of two mutations, 1811+1G>C and 1898+3A>G  Gwendal Dujardin, Diane Commandeur, Catherine Le Jossic-Corcos,

Splicing defects in the CFTR gene: Minigene analysis of two mutations, G>C and A>G  Gwendal Dujardin, Diane Commandeur, Catherine Le Jossic-Corcos,
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma 

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma 
Deficiency of the ADP-Forming Succinyl-CoA Synthase Activity Is Associated with Encephalomyopathy and Mitochondrial DNA Depletion  Orly Elpeleg, Chaya.

Deficiency of the ADP-Forming Succinyl-CoA Synthase Activity Is Associated with Encephalomyopathy and Mitochondrial DNA Depletion  Orly Elpeleg, Chaya.
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma 

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma 
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.

Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.

Similar presentations

Ads by Google